Sukeshi Patel Arora1, Norma S Ketchum1, Joel Michalek1, Jonathon Gelfond1, Devalingam Mahalingam2. 1. Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, 7979 Wurzbach Rd, MC8026, San Antonio, TX, 78229, USA. 2. Cancer Therapy and Research Center, University of Texas Health Science Center San Antonio, 7979 Wurzbach Rd, MC8026, San Antonio, TX, 78229, USA. mahalingam@uthscsa.edu.
Abstract
PURPOSE: Location of the primary tumor is prognostic and predictive of efficacy with VEGF-inhibitors (I) versus EGFR-I given first-line to metastatic colorectal cancer (mCRC) patients. However, little is known regarding the effect of location on prognosis and prediction in refractory mCRC. We assessed the efficacy of VEGF-I and EGFR-I in regards to location of the primary tumor in patients with refractory mCRC enrolled in early phase studies. METHODS: A historical cohort analysis of mCRC patients, including 44 phase I trials our institution, from March 2004 to September 2012. Median Progression free survival (mPFS) and overall survival (mOS) were estimated from Kaplan-Meier curves and groups were statistically compared with the log-rank test. RESULTS: One hundred thirty-nine patients with a median age 59 (33-81). 73.9% received 3+ lines of therapy. All KRAS wild-type patients had received prior EGFR-I. LOCATION: right 20.9%, left 61.9%, and transverse 4.3%. For survival analysis, transverse CRC were included with right. Of the 112 patients, mOS was left (N = 80) 6.6 months versus right (N = 32) 5.9 months, P = 0.18. mPFS was left (n = 86) 2.0 months versus right (N = 35) 2.0 months, P = 0.76. In subgroup analysis, survival was significant for KRAS wild-type patients with left-sided mCRC had mOS of 6.2 months with other agents versus 9.4 months with EGFR-I (P = 0.03). CONCLUSIONS: In phase 1 clinical trials, although location alone was not prognostic in heavily pretreated patients, left-sided mCRC had improved survival with EGFR-I. Despite progression on EGFR-I, left-sided KRAS wild mCRC patients should be considered for phase 1 studies of agents targeting growth factor pathways.
PURPOSE: Location of the primary tumor is prognostic and predictive of efficacy with VEGF-inhibitors (I) versus EGFR-I given first-line to metastatic colorectal cancer (mCRC) patients. However, little is known regarding the effect of location on prognosis and prediction in refractory mCRC. We assessed the efficacy of VEGF-I and EGFR-I in regards to location of the primary tumor in patients with refractory mCRC enrolled in early phase studies. METHODS: A historical cohort analysis of mCRC patients, including 44 phase I trials our institution, from March 2004 to September 2012. Median Progression free survival (mPFS) and overall survival (mOS) were estimated from Kaplan-Meier curves and groups were statistically compared with the log-rank test. RESULTS: One hundred thirty-nine patients with a median age 59 (33-81). 73.9% received 3+ lines of therapy. All KRAS wild-type patients had received prior EGFR-I. LOCATION: right 20.9%, left 61.9%, and transverse 4.3%. For survival analysis, transverse CRC were included with right. Of the 112 patients, mOS was left (N = 80) 6.6 months versus right (N = 32) 5.9 months, P = 0.18. mPFS was left (n = 86) 2.0 months versus right (N = 35) 2.0 months, P = 0.76. In subgroup analysis, survival was significant for KRAS wild-type patients with left-sided mCRC had mOS of 6.2 months with other agents versus 9.4 months with EGFR-I (P = 0.03). CONCLUSIONS: In phase 1 clinical trials, although location alone was not prognostic in heavily pretreated patients, left-sided mCRC had improved survival with EGFR-I. Despite progression on EGFR-I, left-sided KRAS wild mCRC patients should be considered for phase 1 studies of agents targeting growth factor pathways.
Entities:
Keywords:
Colorectal cancer; EGFR inhibitors; Early phase clinical trials; Location
Authors: S Y Brulé; D J Jonker; C S Karapetis; C J O'Callaghan; M J Moore; R Wong; N C Tebbutt; Cr Underhill; D Yip; J R Zalcberg; D Tu; R A Goodwin Journal: Eur J Cancer Date: 2015-05-12 Impact factor: 9.162
Authors: Al B Benson; Tanios Bekaii-Saab; Emily Chan; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Paul F Engstrom; Peter C Enzinger; Marwan G Fakih; Moon J Fenton; Charles S Fuchs; Jean L Grem; Steven Hunt; Ahmed Kamel; Lucille A Leong; Edward Lin; Kilian Salerno May; Mary F Mulcahy; Kate Murphy; Eric Rohren; David P Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; Alan P Venook; Christopher G Willett; Kristina M Gregory; Deborah A Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2013-02-01 Impact factor: 11.908
Authors: Ulrich Nitsche; Fabian Stögbauer; Christoph Späth; Bernhard Haller; Dirk Wilhelm; Helmut Friess; Franz G Bader Journal: Dig Surg Date: 2016-01-30 Impact factor: 2.588
Authors: Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar Journal: Nat Med Date: 2015-10-12 Impact factor: 53.440
Authors: Rene Warschkow; Michael C Sulz; Lukas Marti; Ignazio Tarantino; Bruno M Schmied; Thomas Cerny; Ulrich Güller Journal: BMC Cancer Date: 2016-07-28 Impact factor: 4.430